Event-Driven Stocks

C4 Therapeutics, Inc.

CCCCNasdaq

Healthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 3 good● 3 warning● 1 severedetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$35.9M$35.6M$20.8M$31.1M$45.8M—
Operating income−$115.2M−$119.6M−$139.0M−$129.5M−$82.1M−$60.4M
Net income−$105.0M−$105.3M−$132.5M−$128.2M−$83.9M−$66.3M
Total assets$359.1M$349.6M$376.5M$430.8M$506.8M$400.1M
Total liabilities$102.5M$133.6M$130.3M$141.6M$117.2M$119.3M
Equity$256.6M$216.0M$246.1M$289.2M$389.6M$280.8M
EPS (diluted)$-1.27$-1.52$-2.67$-2.62$-1.82$-5.83
Shares out.71.0M68.6M49.1M48.7M43.1M43.1M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
−320.5%
Net margin
−292.1%
Return on equity
−40.9%
Return on assets
−29.2%
Return on capital (ROCE)
−35.3%
Liabilities / assets
28.5%
Debt / equity
0.40×
Book value / share
$3.61
Revenue growth (YoY)
1.0%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
-2.12distress
Accruals / assets
−1.8%clean
Piotroski F-Score
5/9mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
55
/ 100
Profitability 0Growth 100Catalyst 33Earnings quality 67Financial strength 75

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 1 severe● 3 warning● 3 good
  • Altman Z″ in the distress zone
  • Operating losses (negative operating margin)
  • Reported a net loss
  • Negative operating cash flow
  • Revenue is growing year-over-year
  • Conservative leverage (liabilities < 50% of assets)
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 202621.3M5.8+0.9%
Apr 30, 202621.1M10.9+0.1%
Apr 15, 202621.0M5.0+30.2%
Mar 31, 202616.2M8.4+19.4%
Mar 13, 202613.5M3.7+58.8%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.